Poway, CA (PRWEB) November 15, 2016 -- VetStem has been a long time supporter of the North American Veterinary Regenerative Medicine Association (NAVRMA), a non-profit industry association formed to foster continued research and distribution of information regarding veterinary regenerative medicine for all species. The 2016 Conference will be held in Amelia Island, Florida from November 17th-20th, where VetStem Biopharma will be a platinum sponsor of the event. Dr Robert Harman, VetStem’s founder and CEO, will be presenting on 3 topics during this event. He will present VetStem’s scientific information on two of their latest projects: Adipose-derived stem cells given intravenously improves epistaxis and objective bronchoscopy scoring in horses with exercise-induced pulmonary hemorrhage and A prospective, randomized, blinded and placebo-controlled efficacy study of intraarticular allogeneic adipose stem cells for the treatment of osteoarthritis in dogs. In addition, Dr. Harman was invited to present an industry overview titled “Evolution of Evidence and Regulation in Veterinary Regenerative Medicine.”
“The opportunity to speak at such a prestigious conference and to be a platinum sponsor is an honor and further recognition by the regenerative medicine community of the value of our scientific and educational contributions to the field of regenerative medicine over the past 14 years. We were here at the birth of this industry, have worked with FDA for many years, and intend to provide evidenced-based products for many years to come” stated Dr Harman.
VetStem has always held the belief that scientific evidence, continuing education, and regulatory guidance are the foundation of developing any new technology. VetStem first pioneered adipose-derived stem cell therapy for use in horses for tendon injuries, as an alternative to euthanasia. Just two years after the first horse was treated, VetStem treated the first cat and dog. In 2007 the first peer-reviewed, randomized, double-blinded, placebo controlled, multi-center study using VetStem therapy was published showing intra-articular injection of autologous adipose derived stem cells in the hip joint of a dog decreased patient discomfort and increased patient functional ability. That same year VetStem brought to market the Genesis Platelet Rich Plasma concentration system, as well as the first formal RACE-approved stem cell credentialing continuing education course.
In 2015, VetStem (now VetStem Biopharma) announced the successful completion and peer-reviewed publication of a pilot efficacy study for allogeneic stem cell therapy (93 dogs, multi-center, blinded, placebo controlled) in support of an FDA INADA. The primary end point was statistically significantly improved. VetStem also entered into a distribution and clinical research agreement with Pall LifeSciences on the V-PET™ platelet enhancement therapy system. The V-PET™ is supported by a JAVMA peer reviewed publication of a two center, double-blinded, randomized study in osteoarthritis in dogs.
VetStem is developing multiple stem cell products for FDA-approval that will provide for therapeutic solutions for difficult-to-treat medical conditions in the dog, cat and horse.
About VetStem Biopharma
VetStem Biopharma is a veterinarian-lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 14 years and 12,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 70 issued patents in the field of regenerative medicine.
Kristi Hauta, VetStem Biopharma, http://www.vetstem.com/, +1 858-748-2004 Ext: 208, [email protected]